Halozyme Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company that develops and commercializes proprietary enzyme-based drug delivery technologies and oncology therapies. The company's core ENHANZE platform, powered by the patented recombinant human hyaluronidase enzyme (rHuPH20), facilitates subcutaneous delivery of injectable biologics including monoclonal antibodies, other therapeutic molecules, small molecules, and fluids; it supports partnered products such as DARZALEX FASPRO (subcutaneous), Phesgo, VYVGART Hytrulo, Tecentriq Subcutaneous, and Ocrevus Subcutaneous across oncology, immunology, and neurology indications. Halozyme also commercializes XYosted, a testosterone replacement therapy via an auto-injector, and previously marketed Hylenex and Tlando prior to license terminations. Founded in 1998 and headquartered in San Diego, California, Halozyme operates primarily in the United States with global partnerships enabling international reach through collaborators in pharmaceutical and biotechnology sectors targeting diabetes, cancer, dermatology, autoimmune diseases, and rare disorders. In recent developments, Halozyme completed the acquisition of Elektrofi in late 2025 for up to $900 million, integrating the Hypercon microparticle technology to expand subcutaneous delivery options and strengthen partnerships with big pharma; the deal includes $750 million upfront plus milestones tied to product approvals, with royalties expected from 2030. The company expanded its argenx collaboration with an upfront payment and milestones, secured a new global agreement with Merus N.V. for ENHANZE in bispecific antibodies, and gained regulatory approvals for Roche's Tecentriq and Ocrevus subcutaneous formulations; partners nominated five new targets for clinical advancement in 2024, contributing to record 2024 revenue exceeding $1 billion. These initiatives underscore Halozyme's focus on organic pipeline growth, strategic alliances, and share repurchases up to $250 million.
Anti-AI Investing: The HALO Moat
Implied Volatility Surging for Halozyme Therapeutics Stock Options
Halozyme Therapeutics: Royalty King
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
One of the market's hottest stock themes is buying everything AI can't replace
Roundhill launches "HALO" ETF
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics Q1 Earnings Call Highlights
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Meet The Nvidia HALO Trade: 6 Stocks That May Rise Every Time Jensen Huang Scales AI
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road
Halozyme to Report First Quarter 2026 Financial and Operating Results
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Halozyme Appoints Darren Snellgrove as Chief Financial Officer